Cutting into the New Track of Nucleic Acid Drugs Striving to Lead in Alzheimer’s Vaccines
Targeting the central nervous system axonal regeneration suppressor (NOIs: OMGP, TNR, Nogo-A/66), we use a scalable mRNA vaccine to awaken the endogenous repair capacity, and move towards the functional recovery of neurodegenerative lesions such as Alzheimer's disease at a lower cost and with higher accessibility.
Technology R&D Roadmap
＞55M 152M ＜$100
Global Dementia Patients 2050 Per-dose manufacturing cost
About LifeMoonshot
Our Vision
Our Partnerships
Our Approach
At LifeMoonshot, we envision a world where scientific research and innovation are accessible to all and have the power to transform society. We are committed to advancing the frontiers of knowledge and driving progress through groundbreaking research and discovery.
Our Approach
Our Partnerships
Our Approach
Our approach to research is interdisciplinary and collaborative, bringing together experts from diverse fields to tackle complex challenges and drive innovation. We prioritize projects that have the potential to make a significant impact on society and support researchers throughout the entire research process.
Our Partnerships
Our Partnerships
Our Partnerships
At LifeMoonshot, we believe that collaboration and partnerships are essential to driving progress and advancing scientific research. We work closely with academic institutions, industry partners, and other organizations to support interdisciplinary research and accelerate the pace of discovery.